The Company offers tailored services to their clients in all phases of drug development.
The Company specializes in process optimization to improve effectiveness, reduce risk and increase the probability of successful development and drug approval.
The Company has a team of industry veterans and former regulators who have worked together as a cohesive team for years.
In 2023, the Company yielded $19M in revenue with an Adjusted EBITDA of $9M maintaining a margin of 45+%. The Company is projecting to achieve over $26M in
revenue with $14M Adjusted EBITDA for 2024.
End of 2022 company had WIP $9M and end of year 2023 WIP $22M.
